Current treatment status-Currently treated Posts on Medivizor
Navigation Menu

Current treatment status-Currently treated Posts on Medivizor

Tocilizumab for rheumatoid arthritis: should treatment be extended to every 6 weeks?

Posted by on Sep 29, 2018 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the effects of tocilizumab (Actemra) treatment every 6 weeks in patients with rheumatoid arthritis. They found that tocilizumab every 6 weeks maintains low disease activity for most patients.  Some background Rheumatoid arthritis (RA) is a chronic (long-term) illness. The aim of RA treatment is to...

Read More

Evaluating predictors for poor methotrexate response in patients with rheumatoid arthritis: can co-treatment with adalimumab improve disease symptoms?

Posted by on Aug 28, 2018 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated if there are disease features that can predict if a patient with rheumatoid arthritis will respond well to methotrexate treatment. They found that higher disease activity at early stages of treatment predicted a poor treatment response in these patients. Some background Treatment of rheumatoid arthritis (RA)...

Read More

Upadacitinib: a safe and effective rheumatoid arthritis treatment for patients resistant to csDMARDs

Posted by on Aug 9, 2018 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated whether upadacitinib is a safe and effective treatment for unresponsive patients with rheumatoid arthritis (RA). They concluded that upadacitinib improved RA symptoms in combination with csDMARDs and was well tolerated.  Some background ne type of medication used to treat rheumatoid arthritis...

Read More

Sustaining remission in rheumatoid arthritis and identifying suitable patients for tapered treatment

Posted by on Jul 14, 2018 in Rheumatoid Arthritis | 0 comments

In a nutshell This study examined the features of long-term disease remission in patients with rheumatoid arthritis (RA) on reduced treatment. The study concluded that disease activity, synovitis, rheumatoid factor and a history of smoking are associated with treatment failure. Some background Biological (b)DMARDs (disease-modifying...

Read More

Sarilumab versus adalimumab in the treatment of rheumatoid arthritis – a patient’s perspective

Posted by on Jul 14, 2018 in Rheumatoid Arthritis | 0 comments

In a nutshell This study compared sarilumab and adalimumab for the treatment of rheumatoid arthritis (RA). They found that sarilumab–treated patients reported greater improvements in overall health and disability, quality of life and pain scores. Some background Treatment of rheumatoid arthritis (RA) involves medications to reduce...

Read More

Do glucocorticoid drugs increase the risk of adverse events in patients with rheumatoid arthritis?

Posted by on Jul 14, 2018 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated adverse events associated with glucocorticoid medications in patients with rheumatoid arthritis. The study found that patients with RA have an increased incidence of adverse events associated with the use of glucocorticoids. Some background Treatment of rheumatoid arthritis (RA) involves taking...

Read More

Non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatoid arthritis: a potential risk factor for stroke or heart attack?

Posted by on Jul 14, 2018 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated if non-steroidal anti-inflammatory drugs (NSAIDs) increase the risk of heart attack or stroke in patients with rheumatoid arthritis (RA). They found that non-selective NSAIDs were associated with an increased risk of both stroke and heart attack in RA patients. Some background One type of medication used to...

Read More

Assessing cancer risk in patients using disease-modifying drugs and corticosteroids to treat rheumatoid arthritis

Posted by on Jul 14, 2018 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the risk of skin cancer in patients taking disease-modifying drugs (DMARDs) and corticosteroids to treat rheumatoid arthritis (RA). They concluded that certain DMARDs and corticosteroids are associated with an increased risk of non-melanoma skin cancer. Some background Rheumatoid arthritis (RA) is a...

Read More

The safety of etoricoxib in the treatment of rheumatoid arthritis and osteoarthritis

Posted by on Apr 9, 2018 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the safety of etoricoxib for the treatment of rheumatoid arthritis and osteoarthritis. They found that etoricoxib did not increase the risk of gastrointestinal adverse events. Some background Rheumatoid arthritis (RA) and osteoarthritis (OA) are conditions that cause painful swelling in the joins and bones of...

Read More